Novosti
Khirurgii
This journal is
indexed in Scopus



Year 2009 Vol. 17 No 1

LECTIONS, REVIEWS

YAKUBTSEVICH R.E., SPAS V.V., PROTASEVICH P.P.

ANTICOAGULANT THERAPY AT THE EXTRACORPOREAL DETOXICATION CARRYING OUT IN THE INTENSIVE THERAPY

The important technics of critical conditions treatment in the intensive therapy are the methods of extracorporeal detoxication (hemosorption, hemodialysis, plasmapheresis, hemofiltration and others). It is known that it is necessary to use these or other anticoagulants to prevent extracorporeal contour thrombosis while performing these procedures. Today the diversity of means, methods and ways of anticoagulant therapy makes specialists carrying out the given kinds of treatment choose the most effective and safe one. In the given literature overview the authors have analyzed the data of the modern investigations including multi-central randomized ones.

Keywords: hemosorption, hemodialysis, plasmapheresis, hemofiltration, low-molecular heparins, heparin.
p. 119 - 125 of the original issue
References
  1. , . . : / . . . , 2004.
  2. Davies, H. Anticoagulation in CRRT: agents and strategies in Australian ICUs / H. Davies, G. Leslie // Aust. Crit. Care. 2007. Vol. 20, N 1. P. 15-26.
  3. Continuous veno-venous hemodiafiltration in children after cardiac surgery / A. Jander [et al.] // Eur. J. Cardiothorac. Surg. 2007. Vol. 31, N 6. P. 1022-1028.
  4. Influence of different heparin concentrations on the results of in vitro investigations in plasmaseparation technology using capillary membrane filters / J. K. Unger [et al.] // Artif. Organs. 2003. Vol. 27, N 7. P. 649-657.
  5. Hosokawa, S. Optimization of heparinization in clinical double filtration plasmapheresis / S. Hosokawa, A. Oyamaguchi, O. Yoshida // Int. J. Artif. Organs. 1989. Vol. 12, N 8. P. 544-548.
  6. Amanzadeh, J. Anticoagulation and continuous renal replacement therapy / J. Amanzadeh, R. F. Jr. Reilly // Semin. Dial. 2006. Vol. 19, N 4. P. 311-316.
  7. Tejedor, Alonso M. A Thrombocytopenia and anaphylaxis secondary to heparin in a hemodialysis patient / Alonso M. A. Tejedor // Clin. Nephrol. 2005. Vol. 63, N 3. P. 236-240.
  8. Sulodexide for hemodialysis anticoagulation in heparin-induced thrombocytopenia type II / J. Borawski [et al.] // J. Nephrol. 2007. Vol. 20, N 3. P. 370-372.
  9. Optimal anticoagulation strategy in haemodialysis with heparin-coated polyacrylonitrile membrane / S. Lavaud [et al.] // Nephrol. Dial. Transplant. 2003. Vol. 18, N 10. P. 2097-2104.
  10. Berbece, A. N. Sustained low-efficiency dialysis in the ICU: cost, anticoagulation, and solute removal / A. N. Berbece, R. M. Richardson // Kidney Int. 2006. Vol. 70, N 5. P. 963-968.
  11. Iloprost for additional anticoagulation in continuous renal replacement therapy - a pilot study / J. Birnbaum [et al.] // Ren. Fail. 2007. Vol. 29, N 3. P. 271-277.
  12. Antithrombin supplementation for anticoagulation during continuous hemofiltration in critically ill patients with septic shock: a case-control study / D. du Cheyron [et al.] // Crit. Care. 2006. Vol. 10, N 2. P. R45.
  13. Role of prostacyclin (epoprostenol) as anticoagulant in continuous renal replacement therapies: efficacy, security and cost analysis / F. J. Gainza [et al.] // J. Nephrol. 2006. Vol. 19, N 5. P. 648-655.
  14. Hosokawa, S. Clinical evaluation of nafamstat mesilate (FUT 175). A new anticoagulant for plasmapheresis / S. Hosokawa, A. Oyamaguchi, O. Yoshida // ASAIO J. 1992. Vol. 38, N 1. P. 59-60.
  15. Effect of anticoagulant on biocompatibility in membrane plasmapheresis / S. Omokawa [et al.] // Int. J. Artif. Organs. 1990. Vol. 13, N 11. P. 768-777.
  16. Is regional citrate superior to systemic heparin anticoagulation for continuous renal replacement therapy? A prospective observational study in an adult regional critical care system / S. M. Bagshaw [et al.] // J. Crit. Care. 2005. Vol. 20, N 2. P. 155-161.
  17. Citrate anticoagulation during CVVH in high risk bleeding patients / L. Cubattoli [et al.] // Int. J. Artif. Organs. 2007. Vol. 30, N 3. P. 244-252.
  18. A practical citrate anticoagulation continuous venovenous hemodiafiltration protocol for metabolic control and high solute clearance / A. J. Tolwani [et al.] // Clin. J. Am. Soc. Nephrol. 2006. Vol. 1, N 1. P. 79-87.
  19. Multi-centre evaluation of anticoagulation in patients receiving continuous renal replacement therapy (CRRT) / P. D. Brophy [et al.] // Nephrol. Dial. Transplant. 2005. Vol. 20, N 7. P. 1416-1421.
  20. Improving the delivery of continuous renal replacement therapy using regional citrate anticoagulation / R. Swartz [et al.] // Clin. Nephrol. 2004. Vol. 61, N 2. P. 134-143.
  21. Comparative analysis of procoagulatory activity of haemodialysis, haemofiltration and haemodiafiltration with a polysulfone membrane (APS) and with different modes of enoxaparin anticoagulation / R. Klingel [et al.] // Nephrol. Dial. Transplant. 2004. Vol. 19, N 1. P. 164-170.
  22. Al-Arrayed, S. Use of low molecular weight heparin for hemodialysis: a short-term study / S. Al-Arrayed, R. Seshadri // Saudi J. Kidney Dis. Transpl. 2002. Vol. 13, N 2. P. 146-150.
  23. Safety and efficacy of single bolus anticoagulation with enoxaparin for chronic hemodialysis. Results of an open-label post-certification study / R. Klingel [et al.] // Kidney Blood Press Res. 2004. Vol. 27, N 4. P. 211-217.
  24. Naumnik, B. Unfractionated Heparin but Not Enoxaparin Causes Delayed Plasma PAI-1 Depletion in Hemodialysis Patients: A Prospective Study / B. Naumnik, K. Pawlak, M. Mysliwiec // Clin. Appl. Thromb. Hemost. 2007. Sept. 25.
  25. Enoxaparin but not unfractionated heparin causes a dose-dependent increase in plasma TGF-beta 1 during haemodialysis: a cross-over study / B. Naumnik [et al.] // Nephrol. Dial. Transplant. 2007. Vol. 22, N 6. P. 1690-1696.
  26. The pharmacokinetics of enoxaparin do not correlate with its pharmacodynamic effect in patients receiving dialysis therapies / D. F. Brophy [et al.] // J. Clin. Pharmacol. 2006. Vol. 46, N 8. P. 887-894.
  27. The initial experience of using fraxiparin in extracorporeal detoxication in clinical cardiology / Iu. N. Sirenko [et al.] // Klin. Khir. 1994. N 12. P. 23-25.
  28. Anticoagulation with low-molecular-weight heparin (dalteparin) in plasmapheresis therapy: initial experience / H. Schinzel [et al.] // Transfusion. 2006. Vol. 46, N 4. P. 624-629.
  29. Pharmacokinetics of the low molecular weight heparin enoxaparin during 48 h after bolus administration as an anticoagulant in haemodialysis / B. Guillet [et al.] // Nephrol. Dial. Transplant. 2003. Vol. 18, N 11. P. 2348-2353.
  30. Schneiter, S. Bleeding complication due to accumulation of low-molecular-weight heparin in a patient with renal insufficiency / S. Schneiter, U. Huynh-Do, M. Heizmann // Schweiz. Rundsch. Med. Prax. 2007. Vol. 96, N 18. P. 733-737.
  31. Comparison of effects of different heparins on thrombin activatable fibrinolysis inhibitor in hemodialyzed patients / J. MaByszko [et al.] // Am. J. Nephrol. 2004. Vol. 24, N 6. P. 624-629.
  32. Comparison of low-molecular-weight heparin (enoxaparin sodium) and standard unfractionated heparin for haemodialysis anticoagulation / D. Saltissi [et al.] // Nephrol. Dial. Transplant. 1999. Vol. 14, N 11. P. 2698-2703.
  33. Sabloff, M. The effect of plasmapheresis on the serum activity level of dalteparin: a case report / M. Sabloff, P. S. Wells // Blood Coagul. Fibrinolysis. 2000. Vol. 11, N 4. P. 395-400.
  34. In vitro and in vivo evaluation of enoxaparin removal by continuous renal replacement therapies with acrylonitrile and polysulfone membranes / A. Isla [et al.] // Clin. Ther. 2005. Vol. 27, N 9. P. 1444-1451.
Contacts | ©Vitebsk State Medical University, 2007